BillionToOne is a precision diagnostics company that utilizes a proprietary molecular counting platform to detect and measure DNA molecules at the single-count level. The company focuses on non-invasive prenatal screening and liquid biopsy applications, addressing significant healthcare challenges related to genetic disorders. Its innovative technology aims to improve disease detection and provide actionable insights for patients and healthcare providers.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $152.6M | $71.7M | Not provided |
| YoY Growth | +112.8% | - | - |
| Adjusted Net Loss | -$41.6M | -$82.7M | Not provided |
| Margin % | -27.3% | -115.3% | - |
BillionToOne operates in the precision diagnostics market, competing with established players like Natera, Illumina, and Guardant Health. The company focuses on innovative solutions for prenatal testing and oncology, addressing critical needs in genetic disorder detection.
The company plans to use the proceeds from the IPO to enhance its research and development efforts, expand its operational capabilities, and support the commercialization of its diagnostic products.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.